« | Home | »

How Does Arcapta Neohaler Help Control COPD?

By uds uds | October 2, 2018

Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a collective term used to describe a group of progressive lung diseases. It’s characterized by limited airflow from the lungs which can lead to the development of heart disease, cancer, and other major comorbidities. The most common forms of COPD are chronic bronchitis and emphysema.

COPD is the fourth-leading cause of mortality worldwide and it has been estimated that, by 2020, it will be the fifth leading cause of disability.[1]

COPD Causes, Diagnosis, and Treatment

COPD is caused by long-term exposure to irritants such as chemical fumes, air pollution, dust, and tobacco smoke. Tobacco smoke is the biggest risk factor, as up to 50% of long-term smokers will develop COPD [2]. Additional risk factors include asthma, age, and genetics.

Symptoms often include cough with mucus production, shortness of breath, wheezing, and chest tightness. The end stage of COPD is characterized by worsening symptoms and life-threatening flare-ups.

COPD diagnosis is determined through lung function tests, imaging tests, and blood tests. The disease is not curable, but treatment may relieve symptoms.

What Is Arcapta Neohaler?

Arcapta Neohaler is a novel bronchodilator used for the maintenance treatment of COPD (including chronic bronchitis and emphysema). The active substance, indacaterol, is a long-acting beta agonist bronchodilator.

Many patients buy Arcapta Neohaler from a Canadian online pharmacy at a significant discount compared to retail price. The Canadian or international drug is identical to  the one sold in US pharmacies. However, there might be some cosmetic differences such as the packaging.

How Does Arcapta Neohaler Work?

Arcapta works by relaxing the muscles around the airways, allowing more air to flow through and making it easier to breathe. It also helps to prevent associated symptoms such as coughing, shortness of breath, and wheezing. In comparison to other long-acting bronchodilators, indacaterol is fast-acting (working within 3 to 5 minutes) and extends bronchodilation for up to 24 hours.

Arcapta Neohaler Mechanism of Action

Indacaterol is a beta-(2) agonist that works by stimulating beta-(2) adrenoceptors, located in the smooth muscle of the airways. The interaction causes muscle relaxation and the dilation of the bronchial passages, which become constricted in COPD and asthma patients.

Indacaterol dissociates slowly from the receptor’s membrane, due to its high lipophilic profile and affinity for lung fat-soluble tissues. This characteristic explains the long-lasting activity of the bronchodilator. [3]

How Should I Use the Arcapta Neohaler?

In 2011, Indacaterol was approved by FDA under the trade name Arcapta Neohaler, at a dosage of 75 µg. In Europe, the medication is sold under the trade name Onbrez Breezhaler.

Arcapta Neohaler comes in a clear, colorless, hard gelatin capsule which contains 75 µg of indacaterol. The capsule is to be inhaled once a day. It is for use only in the inhalation device provided.

The capsule must not be swallowed. The bronchodilator starts to work within 5 minutes of inhalation, and its effects can last for up to 24 hours. Detailed instructions for use of Arcapta Neohaler can be found here.

What Are the Possible Side Effects of Arcapta Neohaler?

Along with its relieving and relaxing effects, indacaterol can cause unwanted adverse reactions. The most common side effects include:

A complete list of the side effects of Arcapta Neohaler can be found here.

Treating COPD and Other Similar Diseases

The two most common conditions which contribute to COPD are emphysema and chronic bronchitis. Emphysema is a condition in which the lung alveoli are destroyed. Chronic bronchitis is inflammation of the bronchial tubes lining, characterized with daily cough and mucus production.

Is Asthma Different from COPD?

Asthma – another respiratory tract condition – has a major differential diagnosis to COPD. However, factors such as age, symptom frequency, and triggers, can help determine the difference between both diagnoses.

Generally, asthma is diagnosed in early childhood or adolescence, whereas COPD is diagnosed in mid-life patients (aged 40 or older), who are current or former smokers. Asthma can often be triggered by allergens, cold air, and exercise.

Worsening of COPD symptoms is largely caused by respiratory tract infections, pneumonia, and the flu. It is also possible for COPD and asthma to occur together. [4]

COPD and Asthma Treatment

Both asthma and COPD are incurable conditions. Symptoms of COPD, however, are progressive and lung function is not fully reversible, whereas asthma tends to be more easily controlled. It is important to distinguish between asthma and COPD, as treatment for both conditions is different.

The most common medications for treating COPD are bronchodilators, steroids, and lung therapies. Treatments for asthma typically include quick-relief medicines such as short-acting bronchodilators, long-term control medicines (such as long-acting beta-(2)-agonists and corticosteroids), or immunotherapy.

Arcapta Neohaler and Asthma-Related Death

Arcapta Neohaler (indacaterol) is labeled for the treatment of COPD, including chronic bronchitis and emphysema. The safety and efficacy of this medicine has not been established for the treatment of asthma. Long acting beta-(2)-agonists belong to a class of medications associated with an increased risk of asthma-related deaths. [5], [6]

What Other Medications Can Help Me Treat COPD?

What Other Medications Can Help Me Treat COPD?

Evidence-based guidelines for the treatment of COPD are issued each year by the Global Initiative for Obstructive Lung Disease (GOLD) [7], and the American College of Physicians (ACP) Clinical Practice [8]. These documents recommend COPD treatment based on the COPD stage (I = mild, II = moderate, III = severe, and IV = very severe).

Other treatments for the relief of COPD symptoms include [9]:

One of the best ways to prevent the disease from progressing is to quit smoking and limit environmental exposure to other irritants such as chemical fuels, dust, and air pollution.

What Are Alternatives to Arcapta Neohaler (Indacaterol)?

Inhaled beta-(2)-agonist bronchodilators can be fast-acting (working within 3 to 5 minutes), or slow-acting (taking up to 20 minutes to work). They can be also short-lasting (4-6 hours) or long-lasting (up to 24 hours). Beta-(2)-agonists that are fast-acting and long-lasting provide the most convenient treatment for COPD, bringing quick and long relief to COPD patients. These medications should be taken every 12 to 24 hours.

Commonly available, long-acting beta-(2) bronchodilators include:

Is Arcapta Neohaler an Affordable Medication?

The average US pharmacy price for a one-month supply of indacaterol (30 capsules, each containing 75 µg), is approximately $195. In comparison, a one-month supply of salmeterol (50 µg twice a day) costs approximately the same, and a one-month supply of formoterol (12 µg twice a day) costs approximately $180 [4].

Patients can purchase Arcapta Neohaler at an even lower price through our Canadian online pharmacy, where a one-month supply of indacaterol costs about $126.

Note: medication prices change constantly. Check out Universal Drugstore to get Arcapta Neohaler at the lowest price available online.

How Long Can I Live with COPD?

COPD is a progressive disease which causes increased mortality in the general population. According to a 2009 study, published in the International Journal of Chronic Obstructive Pulmonary Disease, life expectancy reduction is based on smoking status and COPD stage. The results showed that, for a 65-years old male patient, the reduction in life expectancy for stages I, II, III and IV is [2]:

For a smoker:

For a former smoker:

For a non-smoker:

Smokers or former smokers in stages II, III, and IV have the most significant reduction in life expectancy, compared to non-smokers and those with stage I COPD.

Bottom Line: Is Arcapta Neohaler Right for Me?

Arcapta Neohaler (indacaterol), a novel long-acting beta-agonist bronchodilator, is used for the treatment of COPD (including emphysema and chronic bronchitis), because it helps to relax bronchial muscles. Current guidelines for the diagnosis, management, and prevention of COPD indicate that Arcapta Neohaler should be started in patients with stage II (moderate) COPD.

Indacaterol – the active substance of the medicine – is administered at a dosage of 75 µg once per day. It is a safe, effective bronchodilator that offers a convenient once-daily dosage. The substance also has a favorable safety profile and reasonable medication price, compared to other bronchodilators in its class.

Indacaterol has been studied in asthma but is not currently indicated for the treatment. As with other long-acting beta-agonist bronchodilators, the labeling for indacaterol includes a boxed warning regarding the risk of asthma-related death.


[Get Arcapta Neohaler – Lowest Price Available Online]


Disclaimer: The information contained herein is not intended to cover all possible uses, directions, alternative therapies, precautions, warnings, drug interactions, or adverse reactions. Please consult your healthcare provider to ensure Arcapta Neohaler applies to your personal circumstances.


[1] What is Cancer? National Cancer Institute. Accessed on 18 Oct 2018 https://www.cancer.gov/about-cancer/understanding/what-is-cancer

[2] American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. Accessed 18 Oct 2018 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html

[3] Drugs approved for different types of cancer. National Cancer Institute. Accessed on 20 Oct 2017 https://www.cancer.gov/about-cancer/treatment/drugs/cancer-type

[4] 10 Best Selling Drugs 2018 – Oncology. Accessed on 22 Oct 2018 https://www.igeahub.com/2018/05/28/10-best-selling-drugs-2018-oncology

[5] Espinosa, Enrique & Zamora, Pilar & Feliu, Jaime & González Barón, Manuel. (2004). Classification of anticancer drugs – A new system based on therapeutic targets. Cancer treatment reviews. 29. 515-23. doi 10.1016/S0305-7372(03)00116-6.

[6] Classification of Anticancer Drugs. LinkedIn post, published on April 7, 2015. Accessed 25 Oct 2018 https://www.linkedin.com/pulse/classification-anticancer-drugs-harry-an/

[7] Drugs approved for conditions related to cancer, National Cancer Institute. Accessed on 20 Oct 2018 https://www.cancer.gov/about-cancer/treatment/drugs/related-conditions

[8] Top 20 Blockbuster Cancer Drugs, Accessed on 20 Oct 2018 https://www.thebalance.com/top-cancer-drugs-2663234

[9] Global Trends in Oncology, online article published on 15 July 2018. Accessed on 22 Oct [1] Chung VCH, Ma PHX, Hui DSC, Tam WWS, Tang JL. Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis. PLOS ONE. 2013; 8(8): https://doi.org/10.1371/journal.pone.0070784

[2] Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study. International Journal of Chronic Obstructive Pulmonary Disease. 2009;4:137-148

[3] Indacaterol. Accessed on 11 Sep 2018: https://www.drugbank.ca/drugs/DB05039

[4] Slaton RM, Cruthirds DL. Indacaterol (Arcapta Neohaler) for Chronic Obstructive Pulmonary Disease. Pharmacy and Therapeutics. 2012;37(2):86-98.

[5] Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43.doi: 10.1136/thx.2009.116608

[6] Arcapta Prescribing Information. Accessed on 11 Sep 2018: https://www.arcapta.com/Arcapta-Prescribing-Information.pdf

[7] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket guide to COPD Diagnosis, Management, and Prevention (Edition 2017). Accessed on 20 Sep 2018: https://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf

[8] Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. ;155:179–191. doi: 10.7326/0003-4819-155-3-201108020-00008

[9] COPD.2017; Accessed on 10 Sep 2018: https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353685

Topics: | COPD | No Comments »

Comments are closed.